SPRAVATO® (Esketamine) Nasal Spray:
A New Path for Treatment-Resistant Depression
Is Treatment-Resistant Depression (TRD) Holding Your Patients Back?

At PsychCareKS, we understand that when oral antidepressants aren’t enough, the journey toward healing can feel like it’s going in circles. That’s why we offer SPRAVATO®, a revolutionary treatment for Treatment-Resistant Depression (TRD). SPRAVATO® is an FDA-approved nasal spray, used in conjunction with an oral antidepressant, designed to help patients who haven’t found relief with other medications.

What is SPRAVATO®?

SPRAVATO® (esketamine) is a nasal spray indicated for adults with treatment-resistant depression (TRD), or major depressive disorder (MDD) with acute suicidal ideation or behavior. SPRAVATO® provides rapid relief from depressive symptoms when traditional oral antidepressants alone haven’t worked, offering a different approach to managing depression.

When is SPRAVATO® Used?

SPRAVATO® is used in combination with oral antidepressants for:

• Treatment-Resistant Depression (TRD) – For patients who have not responded adequately to two or more different oral antidepressants.

• Depressive Symptoms in Adults with Acute Suicidal Ideation – Helping patients experiencing significant suicidal thoughts or behaviors.

How Does SPRAVATO® Work?

Unlike traditional antidepressants that work through the serotonin and norepinephrine pathways, SPRAVATO® targets NMDA receptors in the brain to help restore balance in mood-regulating systems. This unique mechanism of action offers fast-acting benefits, often providing noticeable symptom relief within 24 hours.

Safety Information and Monitoring Requirements

While SPRAVATO® can be a game-changer for many patients, it is essential to be aware of its safety profile. As with any medication, it is important to consider the potential risks and benefits.

• Sedation and Dissociation – SPRAVATO® can cause sedation, dissociation, or altered states of consciousness. Patients must be monitored for at least two hours post-administration to ensure safety.

• Respiratory Depression – There is a risk of respiratory depression; therefore, healthcare providers will monitor your breathing after administration.

• Suicidal Thoughts and Behaviors – Patients, especially young adults, should be closely monitored for any signs of worsening depression or emergence of suicidal thoughts.

The SPRAVATO® Process at PsychCareKS

Starting SPRAVATO® at PsychCareKS is simple, but first, it’s essential to coordinate with your care team. Here’s how we’ll guide you through the process:

1. Consultation and Evaluation – We’ll discuss your symptoms and history of antidepressant treatments to determine if SPRAVATO® is the right option for you.

2. Treatment Sessions – SPRAVATO® is administered in a comfortable, supervised setting at PsychCareKS. You will be monitored for at least two hours to ensure your safety and comfort.

3. Ongoing Monitoring and Adjustments – Based on your progress, we will adjust your treatment plan as necessary, including the frequency of SPRAVATO® doses, to achieve optimal results.

What to Expect During SPRAVATO® Treatment?

When you begin SPRAVATO® treatment, the process is straightforward:

• Induction Phase (Weeks 1-4): You will receive SPRAVATO® twice a week.

• Optimization/Maintenance Phase (Week 5 Onward): Your dosing frequency will be adjusted to once a week or every two weeks, depending on your response to treatment.

You’ll be in a controlled environment, with a healthcare provider monitoring you during the session. It’s important to note that SPRAVATO® should never be used without the supervision of a healthcare professional due to the potential side effects.

The Benefits of SPRAVATO® at PsychCareKS

• Rapid Relief – Many patients experience noticeable symptom improvements as soon as 24 hours after treatment.

• Proven Results – SPRAVATO® has been shown to outperform traditional oral antidepressants in some cases of TRD.

• Minimized Risk of Sexual Dysfunction – Unlike many oral antidepressants, SPRAVATO® is associated with minimal sexual side effects.

Are You or Your Loved One Struggling with Treatment-Resistant Depression?

If you or someone you know has been battling depression with little to no relief from traditional antidepressants, it may be time to consider SPRAVATO® at PsychCareKS. This innovative treatment option can be a vital step in restoring hope and improving quality of life.

Contact Us for More Information

If you believe SPRAVATO® might be the right treatment for you, or if you’d like more information about its benefits and safety, we invite you to contact our office. Our team at PsychCareKS is here to guide you through every step of the process, from evaluation to treatment and beyond.

Important Safety Information for SPRAVATO®:

• Risk of Sedation, Dissociation, and Respiratory Depression – Please consult with your healthcare provider about the risks.

• Possible Increased Risk of Suicidal Thoughts – Monitor for worsening depression or emerging suicidal thoughts, particularly in young adults.

• Not for Use in Pediatric Patients – SPRAVATO® is not approved for use in children or adolescents.

For a comprehensive overview, please refer to the full prescribing information, including boxed warnings and safety guidelines.